BOK-MCL1 transmembrane interactions: a challenging target for cancer therapy
Por:
M. SANCHO and M. ORZAEZ
Publicada:
2 ene 2021
Ahead of Print:
1 ene 2021
Resumen:
Myeloid cell leukemia 1 (MCL1) gene amplification occurs in a wide range of human cancers and protein overexpression associates with malignant cell growth and evasion of apoptosis. We recently reported that disrupting the interaction between the transmembrane domains of MCL1 and BCL-2 related ovarian killer (BOK) induces cell death, thereby suggesting a new target site for anti-tumorigenic strategies.
Filiaciones:
:
Ctr Invest Principe Felipe, Lab Peptidos & Prot, Valencia 46012, Spain
:
Ctr Invest Principe Felipe, Lab Peptidos & Prot, Valencia 46012, Spain
Green Published, Bronze
|